shutterstock_1395147236_poptika
Poptika / Shutterstock.com
15 August 2023FeaturesBig PharmaAntje Brambrink

UPC: life sciences lead the momentum at new court

On June 1, 2023, the Unified Patent Court (UPC) opened its doors for business. This marked an important milestone in European patent jurisdiction. It provides a new venue for parties in cross-jurisdictional patent disputes.

Both infringement and invalidity claims can be brought in a centralised procedure. A single decision can take effect in up to 17 participating member states of the European Union (UPC states). This is expected to attract many litigants, and the new system even comes along with further advantages such as: extremely fast proceedings, high transparency, potential cost savings compared to multiple parallel national proceedings, and the avoidance of divergent decisions in the countries concerned.

UPC attracts first filers

Since its launch, the UPC has rapidly become an attractive venue for litigants, including global players from various industries. As per July 27, 2023, we noted 28 pending proceedings registered in the court’s case management system (CMS), including:

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
29 June 2023   Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
Big Pharma
26 September 2023   An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.
Big Pharma
23 November 2023   Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.

More on this story

Big Pharma
29 June 2023   Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
Big Pharma
23 November 2023   Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.
Big Pharma
26 September 2023   An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.

More on this story

Big Pharma
29 June 2023   Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
Big Pharma
23 November 2023   Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.
Big Pharma
26 September 2023   An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.